Goodwin Procter Leads Blueprint Medicines Toward $100M IPO
Venture capital-backed Blueprint Medicines Corp., led by a Goodwin Procter LLP team, filed Monday to raise $100 million in an initial public offering, making it the latest biopharmaceutical working toward a...To view the full article, register now.
Already a subscriber? Click here to view full article